

Xyla, 20 mg/ml solution for injection for cattle, horses, dogs and cats

Authorised

- Xylazine hydrochloride

Product identification

Medicine name:

Xyla, 20 mg/ml solution for injection for cattle, horses, dogs and cats

SEDACHEM 20 MG/ML SOLUTION INJECTABLE POUR BOVINS CHEVAUX CHIENS ET CHATS

Active substance:

Xylazine hydrochloride

Target species:

Cattle

Horse

Dog

Cat

Route of administration:

Intravenous use

Intramuscular use

Subcutaneous use

Product details

Active substance and strength:

Xylazine hydrochloride

23.32 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intravenous use:

-

Cattle

- Meat and offal. 1 day
- Milk. 0 hour

-

Horse

- Meat and offal. 1 day
- Milk. 0 hour

-

Dog

Intramuscular use:

-

Cattle

- Meat and offal. 1 day
- Milk. 0 hour

-

Dog

-

Cat

Subcutaneous use:

-

Cat

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN05CM92

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

France

Package description:

50 ml clear, type II glass bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. Package size: 5x50 ml in a cardboard box.

50 ml clear, type II glass bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. Package size: 1x50 ml in a cardboard box.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Interchemie Werken De Adelaar Eesti AS

Marketing authorisation date:

19/10/2020

Manufacturing sites for batch release:

Interchemie Werken De Adelaar Eesti AS

Responsible authority:

French Agency For Food, Environmental And Occupational Health & Safety

Authorisation number:

FR/V/3192547 5/2020

Date of authorisation status change:

19/10/2020

Reference member state:

Estonia

Procedure number:

EE/V/0105/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Finland France
Germany Greece Hungary Iceland Ireland Italy Latvia Malta Netherlands
Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Source URL: <https://medicines.health.europa.eu/veterinary/600000027450>